GlobeImmune, Inc. Announces Presentation of Pre-Clinical Data on GI-10001 for Chronic Myelogenous Leukemia (CML) at International Conference on Molecular Targets and Cancer Therapeutics
25 oct. 2007 06h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - October 25, 2007) - GlobeImmune, Inc. announced today results
from research on its GI-10001 Tarmogen® which is being investigated for
the treatment of drug...
GlobeImmune Raises $41.2 Million in Series C Financing
26 sept. 2007 06h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - September 26, 2007) - GlobeImmune, Inc. today announced it has
raised $41.2 million through a Series C Preferred Stock financing. This
round was led by Wexford Capital...
GlobeImmune Updates Speaking Date and Time at the JPMorgan Healthcare Conference
05 janv. 2007 12h23 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO -- (MARKET WIRE) -- January 5, 2007 -- GlobeImmune, Inc. announced today that
President and Chief Executive Officer Timothy C. Rodell, M.D. will present
at the JPMorgan Healthcare...
GlobeImmune CEO to Present at JPMorgan Healthcare Conference
03 janv. 2007 12h36 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO -- (MARKET WIRE) -- January 3, 2007 -- GlobeImmune, Inc. announced today that
President and Chief Executive Officer, Timothy C. Rodell, M.D., will
present at the JPMorgan Healthcare...
GlobeImmune Announces Presentation of Positive Interim Results From a Study of the GI-5005 Tarmogen in Patients With Chronic Hepatitis C Infection
30 oct. 2006 08h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO -- (MARKET WIRE) -- October 30, 2006 -- GlobeImmune, Inc. today announced positive
interim results from Study GI-5005-01, a randomized, placebo-controlled,
multi-center,...
GlobeImmune Announces GI-5005 Tarmogen Data for Chronic Hepatitis C Infection to Be Presented at the American Association for the Study of Liver Diseases (AASLD)
17 oct. 2006 12h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO -- (MARKET WIRE) -- October 17, 2006 -- GlobeImmune, Inc. announced today that the
interim results from a placebo-controlled Phase 1b study of GI-5005 in
patients chronically infected...